ASX:EMDPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Emyria Ltd
$0.037
$0.001 (2.63%)
Day Range
$0.037 – $0.039
52 Week Range
$0.025 – $0.078
Volume
1.62M
Avg Volume (10D)
1.12M
Market Cap
$29.84M
Price Chart
Market Statistics
Open$0.038
Previous Close$0.038
Day High$0.039
Day Low$0.037
52 Week High$0.078
52 Week Low$0.025
Valuation
Market Cap29.84M
Shares Outstanding806.56M
Price to Book2.53
Trading Activity
Volume1.62M
Value Traded61.11K
Bid$0.037 × 1,834,599
Ask$0.038 × 74,939
Performance
1 Day-2.56%
5 Day-2.56%
13 Week-20.83%
52 Week40.74%
YTD-35.59%
Technical Indicators
RSI (14)37.11
50-Day SMA$0.044
200-Day SMA$0.053
Latest News
Biotechnology
Emyria Poised for Operational Boost as TGA Broadens Psych-Therapy Prescriber Access
Emyria is set to accelerate recruitment as TGA broadens Authorised Prescriber roles for psychedelic therapy, boosting Empax network expansion into H2 2026.
Biotechnology
Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria unveils Empax global partnership platform to link international sponsors with its clinical delivery network; Psyence signs for Phase IIb trial.
Biotechnology
Emyria Introduces First Empax Centre to Victoria with Expanded Medibank Funding Agreement
Emyria expands Medibank funding to Victoria, unlocking Empax TRD/PTSD care at Avive Mornington Peninsula; nationwide rollout underway.
Biotechnology
Emyria Establishes First Victorian Empax Clinic for Psychedelic-Assisted Treatments
Perth-based mental health care specialist Emyria (ASX: EMD) has secured its first Empax clinic in Victoria for the psychedelic-assisted treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.